tiprankstipranks
ABIONYX Pharma SA (GB:0RAG)
LSE:0RAG
Holding GB:0RAG?
Track your performance easily

ABIONYX Pharma SA (0RAG) Income Statement

0 Followers

ABIONYX Pharma SA Income Statement

Last quarter (Q2 2022), ABIONYX Pharma SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, ABIONYX Pharma SA's net income was €―. See ABIONYX Pharma SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-€ 675.00K€ 0.00€ 0.00€ 174.00K€ 0.00
Cost of Revenue
-€ 416.00K€ 0.00€ 0.00€ 0.00€ 0.00
Gross Profit
-€ 259.00K€ 0.00€ 0.00€ 174.00K€ 0.00
Operating Expense
-€ 6.21M€ 2.97M€ 2.52M€ 7.23M€ 6.64M
Operating Income
-€ -5.95M€ -2.97M€ -2.52M€ -7.05M€ -6.64M
Net Non Operating Interest Income Expense
-€ 148.00K€ 1.04M€ 4.44M€ 775.00K€ 1.91M
Other Income Expense
------
Pretax Income
-€ -5.82M€ -1.89M€ 1.89M€ -6.30M€ -4.98M
Tax Provision
-€ 0.00€ 0.00€ 38.00K€ 1.00K€ 2.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -5.82M€ -1.89M€ 1.85M€ -6.30M€ -4.98M
Basic EPS
-€ -0.23€ -0.08€ 0.09€ -0.34€ -0.27
Diluted EPS
-€ -0.23€ -0.08€ 0.09€ -0.34€ -0.27
Basic Average Shares
-€ 24.88M€ 22.51M€ 20.60M€ 18.58M€ 18.25M
Diluted Average Shares
-€ 25.92M€ 23.49M€ 21.12M€ 19.62M€ 19.04M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----€ 120.00K€ 146.00K
Total Expenses
-€ 6.63M€ 2.97M€ 2.52M€ 7.23M€ 6.64M
Net Income From Continuing And Discontinued Operation
-€ -5.82M€ -1.89M€ 1.85M€ -6.30M€ -4.98M
Normalized Income
-€ -5.82M€ -1.89M€ 1.85M€ -6.30M€ -4.98M
Interest Expense
-€ 8.00K€ 0.00€ 350.00K€ 0.00€ 167.00K
EBIT
-€ -5.81M€ -1.89M€ 2.24M€ -6.30M€ -4.81M
EBITDA
-€ -5.70M€ -1.89M€ 2.25M€ -6.26M€ -4.22M
Currency in EUR

ABIONYX Pharma SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis